Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.

被引：0
|
作者：
Kelly, Ronan Joseph
Le, Hannah
Wu, Sze-Jung
Laurie, Melissa
Raval, Amit D.
Shi, Qian
Korytowsky, Beata
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[3] HealthCore, Wilmington, DE USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e16035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer.
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16016 - E16016
  • [22] BURDEN OF ILLNESS AND TREATMENT PATTERNS OF ADULT PATIENTS WITH ADVANCED OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER: A SYSTEMATIC LITERATURE REVIEW
    Chen, Z.
    Ajani, J.
    Yusuf, A.
    Eichinger, C.
    Majer, I
    VALUE IN HEALTH, 2023, 26 (12) : S43 - S43
  • [23] HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT
    Gomez-Ulloa, D.
    Amonkar, M.
    Kothari, S.
    Cheung, W. Y.
    Chau, I
    Zalcberg, J. R.
    Nuria, L.
    Falcone, A.
    VALUE IN HEALTH, 2018, 21 : S144 - S144
  • [24] PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).
    Ding, Xuewei
    Wang, Xuejun
    Li, Bin
    Wang, Longgang
    Guo, Honghai
    Shang, Liang
    Huang, Wenbai
    Wu, Liangliang
    Ke, Bin
    Liu, Yong
    Liu, Ning
    Wang, Baogui
    Cai, Mingzhi
    Deng, Jingyu
    Zhang, Rupeng
    Zhang, Jiancheng
    Chai, Jie
    Zhao, Qun
    Li, Leping
    Liang, Han
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 364 - 364
  • [25] Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO plus chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC)
    Chau, Ian
    Barzi, Afsaneh
    Zhang, Ying
    You, Min
    Bertwistle, David
    Davis, Catherine
    Chen, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 295 - 295
  • [26] Tumor Treating Fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial
    Li, J.
    Cang, S.
    Ling, Y.
    Lam, K. O.
    Chen, Y.
    Xu, Y.
    Yang, Y.
    Lavy-Shahaf, G.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1455 - S1455
  • [27] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Lei, Ming
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Wang, Xuya
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Li, Mingshun
    Poulart, Valerie
    Wang, Yu
    Doshi, Parul
    Shitara., Kohei
    CANCER RESEARCH, 2022, 82 (12)
  • [28] Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study
    Le, Dung T.
    Bendell, Johanna C.
    Calvo, Emiliano
    Kim, Joseph W.
    Ascierto, Paolo Antonio
    Sharma, Padmanee
    Ott, Patrick Alexander
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    De Braud, Filippo G.
    Chau, Ian
    Christensen, Olaf
    Harbison, Christopher
    Lin, Chen-Sheng
    Janjigian, Yelena Yuriy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Cheng, Xiaojiao
    Li, Qingli
    Tu, Shuiping
    Chen, Xiaobing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] First-line (1L) treatment patterns in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (GC/GEJC/EAC): Data from the Spanish AGAMENON-SEOM registry
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    Gallego Plazas, J.
    Custodio, A.
    Visa, L.
    Martinez de Castro, E.
    Gomez Gonzalez, L.
    Moreno Gutierrez, M.
    Polanco Sanchez, C.
    Xiao, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S258 - S258
12345